Oct 02, 2020 8:40am EDT Algernon Announces 75% Enrollment in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Sep 29, 2020 8:00am EDT Algernon Announces Enrollment of 100 Patients in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Sep 22, 2020 8:00am EDT Algernon Announces 50% Enrollment in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Sep 16, 2020 8:00am EDT Algernon Announces Data and Safety Monitoring Board Recommends the Continuation of its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Sep 02, 2020 8:30am EDT Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Aug 25, 2020 8:00am EDT Algernon to Provide Update on its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
Aug 24, 2020 7:00am EDT Algernon Announces Research Analyst Coverage by Mackie Research with an $0.80/share Target Price
Aug 17, 2020 8:00am EDT Algernon CEO Presents Corporate Update Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
Aug 13, 2020 8:15am EDT Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
